POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases
Modern Pathology · 2025-03 · 38 (3) · 100676
DOI: 10.1016/j.modpat.2024.100676 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Pathology, 2025-03. Verfasst von Phoebe M Hammer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Carcinosarcoma, Uterine Neoplasms, Mutation, DNA Polymerase II. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Uterine carcinosarcomas (UCS) are high-grade biphasic neoplasms with generally poor outcomes. Based on The Cancer Genome Atlas molecular classification of endometrial carcinomas, the majority of UCS are classified as copy-number high/serous-like (p53-abnormal); however, a small subset represent other molecular subtypes, including those that harbor POLE mutations. We identified 11 POLE-mutated (POLEmut) UCS across 3 institutions and assessed the clinical, histopathologic, immunohistochemical, and molecular features of these tumors. POLEmut UCS occurred in adult women (median age, 64 years; range, 48-79 years) and usually presented as The International Federation of Gynecology and Obstetrics 2009 clinical stage IA (n = 4) or IB (n = 3). Almost all tumors were predominantly carcinomatous (n = 10), with most showing endometrioid morphology (n = 7), followed by ambiguous (n = 4) and serous (n = 3) histotypes. By immunohistochemistry, 7 tumors showed aberrant or subclonally aberrant expression of p53, 6 of which harbored pathogenic mutations in TP53 by sequencing. Other frequent mutations included PIK3CA (10/11), PTEN (8/11), RB1 (7/11), ARID1A (7/11), ATM (6/11), PIK3RA (5/11), and FBXW7 (4/11). Two tumors demonstrated loss of mismatch repair protein expression, and 1 had subclonal loss. Heterologous differentiation was uncommon, and only chondrosarcomatous type (n = 2) was observed. Mean and median follow-ups were 24.3 and 14.1 months, respectively (range, 1.4-61.1 months). Ten patients (91%) had no recurrences or death from disease, although 3 of these had follow-up periods
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University School of Medicine, Stanford, California.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Pathology, Stanford University School of Medicine, Stanford, California. Electronic address: bhowitt@stanford.edu.
Zitieren
APA
Hammer, P. M., Momeni-Boroujeni, A., Kolin, D. L., Kingsley, L., Folkins, A., Geisick, R. L. P., Ho, C., Suarez, C. J., & Howitt, B. E. (2025). POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases. Modern Pathology, 38(3), 100676. https://doi.org/10.1016/j.modpat.2024.100676
Vancouver
Hammer PM, Momeni-Boroujeni A, Kolin DL, Kingsley L, Folkins A, Geisick RLP, et al. POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases. Modern Pathology. 2025;38(3):100676. doi:10.1016/j.modpat.2024.100676
BibTeX
@article{Hammer2025,
author = {Hammer, Phoebe M and Momeni-Boroujeni, Amir and Kolin, David L and Kingsley, Leandra and Folkins, Ann and Geisick, Rachel L P and Ho, Chandler and Suarez, Carlos J and Howitt, Brooke E},
title = {POLE-Mutated Uterine Carcinosarcomas: A Clinicopathologic and Molecular Study of 11 Cases},
journal = {Modern Pathology},
year = {2025},
volume = {38},
number = {3},
pages = {100676},
doi = {10.1016/j.modpat.2024.100676}
}
EUVIMED